FIELD: medicine.
SUBSTANCE: method involves determining matte glass area in lung and thrombin-antithrombin complex content in patient blood before and after 1 treatment month. Matte glass area dropping more than by 30% and thrombin-antithrombin complex characteristics becoming 1.8 times as low in a month after starting treatment when compared to the initial values, good therapy effectiveness is considered to be the case.
EFFECT: high accuracy in determining treatment effectiveness.
1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPUTER-AIDED DIAGNOSIS METHOD FOR DETERMINING PULMONARY HYPERTENSION SEVERITY | 2004 |
|
RU2269931C1 |
| METHOD FOR PREDICTION OF PULMONARY FIBROSIS DEVELOPMENT IN PATIENTS WITH INTERSTITIAL LUNG DISEASES | 2022 |
|
RU2796612C1 |
| METHOD FOR DIAGNOSING AUTOIMMUNE PATHOLOGY | 1999 |
|
RU2146371C1 |
| METHOD FOR DIAGNOSING INFLAMMATION PROCESSES IN BRONCHOPNEUMONIC SYSTEM | 1998 |
|
RU2131608C1 |
| METHOD FOR EVALUATING ANTIOXIDATION PROTECTION STATE IN LUNG DISEASE PATIENTS (SARCOIDOSIS, FIBROSING ALVEOLITIS, LARVAL PARAGONIMIASIS) | 1998 |
|
RU2152620C1 |
| METHOD OF DIAGNOSING AND MONITORING CLINICAL COURSE OF LUNG DISEASES ACCOMPANIED BY ACCUMULATION OF PROTEIN AND LIPID SUBSTANCES IN ALVEOLI | 2014 |
|
RU2593229C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF PULMONARY SARCOIDOSIS AND FIBROSING ALVEOLITIS | 0 |
|
SU1758558A1 |
| METHOD OF DIAGNOSIS OF IMMUNOCOMPLEX INJURES OF THE LUNGS | 0 |
|
SU1273059A1 |
| METHOD FOR PREDICTING CLINICAL COURSE OF BRONCHOPULMONARY DISEASES AND PULMONARY CARCINOMA | 2005 |
|
RU2280868C1 |
| METHOD FOR DETERMINING THE LEVEL OF RESECTION DURING OPERATIVE THERAPY IN PATIENTS WITH EMPHYSEMA | 2017 |
|
RU2650592C1 |
